Ischaemic heart disease is the leading cause of death and disability in Europe and worldwide. As such, new treatments are urgently needed to protect the heart muscle from injury, especially in those patients having a heart attack – a treatment strategy termed ‘cardioprotection’. Experimental research has provided many insights into how we can protect the heart muscle and improve functional recovery after a heart attack to prevent heart failure – this has resulted in the discovery of many new cardioprotective treatments.
The objective of COST Action (CA 16225 EU-CARDIOPROTECTION) ‘Realising the therapeutic potential of novel cardioprotective therapies’ is to translate these new cardioprotective therapies from the experimental studies into the hospital setting for patient benefit.
EU-CARDIOPROTECTION brings together researchers from over 25 European countries. Work Group 3, Confounders is co-chaired by Pharmahungary Group Founder & CEO, Prof. Peter Ferdinandy, MD, PhD, MBA. The objective of WG3: “The mechanisms through which co-morbidities and co-medications confound cardioprotection are not known and will be systematically investigate here for the first time. Understanding these mechanisms may provide new insights into the cardioprotective signalling pathway. The COST Action will identify the most important co-morbidities and co-medications to target in pre-clinical and clinical cardioprotection studies.”